As branded drugs have become more complicated and global growth has
become more important to generic franchises, scale matters more than
ever. That's a definite check mark in the plus column for Mylan (NASDAQ: MYL )
, as it is among the largest generic drug makers in the world and one
of the few with the scale and capability to operate not only
efficiently, but to crack the code on hard-to-manufacture generics.
Wall Street is definitely keen on the shares right now. The stock has
risen almost 80% over the last year, and more than 140% over the last
two years, as investors have gotten excited about the potential for
generic Lidoderm, Copaxone, and Advair, as well as the potential for
additional value-creating M&A deals.
Follow this link for more:
Is Mylan a Good Buy?
No comments:
Post a Comment